NovaBridge Biosciences (NBP) Cash from Operations (2019 - 2025)
NovaBridge Biosciences (NBP) posted quarterly Cash from Operations of 14596000.0 for Q4 2025, down 33.31% year-over-year from 21886004.38 in Q4 2024, and down 893.69% quarter-over-quarter from 1839000.0 in Q3 2025.
Powered by 
Analysis
NovaBridge Biosciences (NBP) Cash from Operations (2019 - 2025) Analysis & Trends
NovaBridge Biosciences (NBP) has reported Cash from Operations for 4 consecutive years, with 14596000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Cash from Operations fell 33.31% year-over-year to 14596000.0; the TTM figure through Dec 2025 stood at 15284000.0 (down 112.72% YoY), while the FY2025 annual figure was 20597000.0, up 60.89% from the prior year.
- Cash from Operations declined to 14596000.0 in Q4 2025 per NBP's latest filing, from 1839000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 8422000.0 in Q3 2024 and bottomed at 14596000.0 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn | -526.00 Mn |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - | -387.32 Mn |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 462.82 Mn |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn | 326.72 Mn |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - | 728.46 Mn |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 10 | NovaBridge Biosciences | 199.33 Mn | 199.33 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -14.60 Mn |
| Sep 30, 2025 | 1.84 Mn |
| Dec 31, 2024 | -10.95 Mn |
| Sep 30, 2024 | 8.42 Mn |
| Dec 31, 2020 | 153.34 Mn |
| Dec 31, 2019 | -30.64 Mn |